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Immune Checkpoints in Cancer Treatment
M. Cherubino
Department of Biology, Gettysburg College, Gettysburg, PA

Overview
Despite the human immune system, cancer thrives in an extremely hostile
environment. Cancer is the second most common cause of death in the
U.S. with about 600,000 deaths every year, and cancer is expected to
surpass heart disease as the most common cause of death in the
U.S. Immune checkpoint inhibitors are a novel and promising therapeutic
for treating cancer in its late stages.

Treatment Mechanism
The invention of ipilimumab, the first successful immune checkpoint
inhibitor, marked the inception of a new era in cancer treatment.
Immune checkpoint inhibitors like ipilimumab and nivolumab (anti-PD1) block the immune suppression pathway by mimicking the
suppression ligand that binds to either PD-1 or CTLA-4 (see Figure
3.). The binding of these antibodies is irreversible, thus allowing the
bonded CTL to be uninterrupted as it carries out instructions from the
costimulatory pathway. The resulting clonal expansion of CTLs specific
to the cancer antigen leads to a robust immune response to the
cancer cells. The randomness of which molecules bump into other
molecules is a critical component to the success or failure of immune
checkpoint cancer treatments. After all, both PD-L1 and CD80/CD86
and their mimicking antibodies bind irreversibly to their respective PD1 or CTLA-4. Although several minor factors influence the probability
that a protein will meet its ligand, the process is largely random. For
the purpose of simplicity, the actual probabilities can be adequately
represented by a random system. In order to best understand this
situation, consider Figure 3. mathematically.

Background
The human immune system evolved to detect and
respond to antigens, or foreign insults. When a cell
detects an antigen from within, through a series of
events, the cell presents the antigen to the immune
system via a major histocompatibility complex type I
(MHCI). Most of the time, MHCs are non-presenting.
When in this state, the immune system cannot detect
foreign insults, thus the immune system does not
mount an immune response. For example, when MHCI
is non-presenting, a T cell receptor (TCR) will not bind
to MHCI, thus no interaction occurs (see Figure
1.). For a long time, many researchers hypothesized
that transformed cells, cancerous cells derived from
within normal cells, used the host cell to disguise its
insult from the immune system. Researchers now
believe that in many cases,
Figure 1. No interaction between a normal,
this hypothesis is false.
untransformed cell and a cytotoxic T cell.

In cancer patients, the immune
system often detects the insult by
recognizing a cancer antigen in
MHCI. A cytotoxic T lymphocyte
(CTL), a staple component of the
acquired immune response, binds
to the antigen-presenting MHCI at
the TCR. Cytokines, small
molecules that assist in immune
responses, facilitate the formation
of a costimulatory pathway.
Different cell types carry different
surface proteins and ligands. Two
such sets of surface protein and
ligand are shown in Figure 2. The
study of how these pathways form
is an active research area. The
CD80/CD86 and CD28
Figure 2. Immune response suppressed
costimulatory pathway is as
by immune suppression pathway.
necessary as the MHCI and TCR
pathway. This costimulatory pathway, referred to as the cell proliferative
pathway, signals the cytotoxic T cell to clonally expand to around 10^15
copies. If created, all of these copies would be programmed with the
directive to kill cancer cells bearing a cancer antigen. However, cancer
cells make use of the suppression pathway to silence instructions from the
costimulatory pathway.
One suppression pathway is the PD-L1 and PD-1 pathway. When both
pathways are simultaneously delivering instructions to the CTL, the CTL
becomes inactive or dies. In addition to dominance, when both pathways
are active CD80/CD86 of the suppression pathway sometimes (if bonding
attractions are strong enough) has the ability to break the costimulatory
pathway in a process called transendocytosis.

Treatment Information
Many immune checkpoint inhibitors are in clinics and development today.
These inhibitors extend the life of a terminally ill patient or serve as a
safeguard accompanying removal of cancerous tissue. Ipilimumab and
nivolumab are most often used to extend life by treating late stage,
metastatic melanoma and lung cancer. In a study, ipilimumab plus
dacarbazine (a chemotherapeutic) were found to have a five-year survival
rate of 18.2% versus the 8.8% five-year survival rate of placebo plus
dacarbazine (see Figure 5.). Nivolumab and other immune checkpoint
inhibitors offer similar results for their respective cell types. All approved
immune checkpoint inhibitors have around a 20% five-year survival rate.
Inhibitor cocktails can sometimes lead to better results at the cost of higher
toxicity.

Given 1 PD-1, 1 PD-L1, and 4 anti-PD-1, what is the probability that
the immune suppression pathway will be blocked? What is the
probability that the pathway will be active?

Acknowledgments

PD-1 may bind to PD-L1 to activate the immune suppression pathway,
or it may bind to one of the four anti-PD-1 ligands to block the
pathway.

Figure 3. Immune response enabled by blocking
of the immune suppression pathway.

4 block / 5 total = 0.8 block
1 activate / 5 total = 0.2 active
In an environment with many transformed cells, some are likely to
survive. The daughter cells of the survivors do not inherit PD-1, and
are thus vulnerable to the effect of the drugs.

While this treatment shows promise by hindering cancer, it is very
unlikely to cure cancer. Figure 4. illustrates a cancer cell’s common
and rapid adaptation to its new, hostile environment. Again,
mathematics can be used to easily visualize the significance of the
situation.
Given 1 PD-1, 30 PD-L1, and 4 anti-PD-1, what is the probability that
the immune suppression pathway will be blocked? What is the
probability that the pathway will be active?
PD-1 may bind to one of the thirty PD-L1 to activate the immune
suppression pathway, or it may bind to one of the four anti-PD-1
ligands to block the pathway.
4 block / 34 total = 0.1 block
30 activate / 34 total = 0.9 active

Figure 4. Immune response suppressed by
immune suppression pathway, despite
immune checkpoint cancer treatment.

Clearly, the adaptation is devastating to the success of anti-PD-1. In
most cases, the adaptation is likely caused by a specific aneuploidy
rather than by mutation, which would explain both its relatively large
frequency and short lag time. Cancer cells without the adaptation are
likely to die. Cancer cells with the adaptation are likely to survive. The
drugged environment selects for cells with the adaptation and against
the cells without the adaptation. This selection results in a bottleneck
effect. Most survivors emerge resistant to the new environment, and
their unhindered cell division leads to large populations of resistant
cancer cells.

Figure 5. Phase III study compares the living proportion treated with
ipilimumab plus dacarbazine (blue) and the living proportion treated
with placebo plus dacarbazine (yellow), both vs. months elapsed.
Symbols indicate censored observations. n=247, n=251.
Bristol-Myers Squibb is a major company in the development of these
immune checkpoint inhibitors. Bristol-Myers Squibb prices ipilimumab
(brand name YERVOY) at $30,000 per dose. Each dose consists of
3mg/kg every three weeks. A regimen typically consists of four consecutive
doses, which brings the total cost of treatment to $120,000; however, a
patient-assistance program may reduce the price to $80,000. All immune
checkpoint inhibitors cost around $150,000 for one year of treatment. The
medication is administered regularly until progression of the disease or
until toxicity becomes intolerable.

Conclusions
Immune checkpoint inhibitors, such as ipilimumab and nivolumab, block
the suppression pathway of cancer cell interaction with T cells. This
mechanic stimulates the proliferation of T cells, which can result in a
robust immune response to metastatic melanoma, among other cancers.
Immune checkpoint inhibitors tend to produce around a 20% five-year
survival rate.
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